Replies to post #33835 on Enzolytics Inc (ENZC)

[Up/DownTrader]

Yes!! Frick-it!! GO ENZC, for God's sake & the sake of Planet Earth!!!!!

[cjstocksup]

Anyone who reads the news about the Binding merger about to close now and the UC Davis of CA studies will be loading and holding ENZC for silver coins above ahead that should be closer than most think!

[cjstocksup]

PLANO, TX / ACCESSWIRE / October 1, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) or (the "Company") today announced the addition of Charles Cotropia to the Company's Board of Directors. ENZC entered into a Letter of Intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), a biotech company located in Dallas Texas, on September 15, 2020. In addition, the Company announces that Harry Zhabilov, CEO of ENZC will also be joining the Board of Directors of BioClonetics. The additions to the boards of ENZC and BCLS is expected to assist each group to complete their due diligence more rapidly in order to move to definitive agreements and prepare for a smooth transition upon completion of the transaction.

BioClonetics is in the final stage of development of a parent monoclonal antibody ("mAb") (designated as Clone 3), which is non-toxic and has shown in initial in vitro testing to be effective against more than 95% of all strains and viral subtypes of HIV-1 against which it has been tested.

[www.bioclonetics.com/validation.html]. The recombinant form of the parent mAb have been produced and are being tested.

The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates.

Thereafter, additional PBMC based in-vitro neutralization studies will be conducted with the BioClonetics Clone 3 recombinant antibodies in combination with the Enzolytics ITV-1 peptide. Based on the results, the best combination with be tested in primate studies at the California National Primate Research Center University of California, Davis, California.

In anticipation of ENZC bringing current its OTC filings the Company has made application to OTC Markets for membership. Once the Membership Application is approved by OTC Markets, the Company will begin filing its delinquent quarters.

The proposed merger anticipated in the non-binding LOI will result in Charles Cotropia being appointed as CEO of the merged entity and Harry Zhabilov and Joseph Cotropia, MD, being appointed as co-CSO. Gaurav Chandra, MD, will serve as COO of the merged entity. Additional details will be disclosed as the transaction progresses.

"The addition of Charles to our board will allow Charles access as a Board member to certain technical information that will give him an in depth understanding of our patented technology", stated Harry Zhabilov, CEO of ENZC.

Charles Cotropia, CEO of BioClonetics added, "We are looking forward to negotiating the terms of the merger for our two entities and bringing our therapies to market upon completion of clinical trials."



Read more: http://www.digitaljournal.com/pr/4825858#ixzz6ZcsaKADw